Expert Interview
A Second View: Looking at Revolution Medicine's RMC-6236 and the results to date prior to their RASolute 302 Phase 3 Trial
Ticker(s): RVMDInstitution: Duke University
- Gastrointestinal Oncologist and Professor of Medicine in the Department of Surgery at Duke University
- Manages 30+ patients with pancreatic cancer
- Research interest in immune therapies for treating GI cancers
Roughly how many pancreatic cancer patients do you manage?
Added By: ben_adminHow do you view the mechanism of action of RMC-6236?
Added By: ben_adminWhat is your impression of the side effect profile and efficacy demonstrated in Revolutions Phase 3 trial?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
